Use the Pediatric Dosing Calculator for fast, accurate dosing
The DEFINITY® Educational Series
The DEFINITY® Educational Series is designed to increase the quality and efficiency of scans, reduce unnecessary medical costs, enhance diagnostic accuracy, and improve adherence to UEA guidelines
Through the DEFINITY® Educational Series, Lantheus provides you with institutional and educational value presentations, webinars, and an operational efficiencies toolkit. They aim to:
- Drive clinical and diagnostic value across stakeholders
- Deliver clinical and technical support
- Support the efficient implementation of DEFINITY® across clinical settings
- Optimize DEFINITY® images
- Help to integrate UEA policy
- Help echo lab with sonographer administration of DEFINITY®
CLINICAL SPECIALIST PROGRAMS
See SUPPORT in High DEF(INITY)™
Dedicated on-site clinical and technical support delivered by expert sonographers to assist with the efficient implementation of DEFINITY®.*
INFORMATIONAL WEBINARS
See KNOWLEDGE in High DEF(INITY)™
Live and on-demand webinars designed to provide timely and important information on the use, implementation, and impact DEFINITY® has on cardiac diagnosis, patient management, and cost-effectiveness in echocardiography.* Topics include:
- Cardiac diagnosis and patient management
- Case study review
- Contrast echo in critical care
- DEFINITY® across multiple care settings
- DEFINITY® implementation and administration
- DEFINITY® safety profile
- Guidelines and standards
- Image optimization
- Improving patient outcomes
- Optimizing the value of DEFINITY®
- Quality-driven echocardiography
- Workflow efficiency
OPERATIONAL TOOLKIT
See GUIDANCE in High DEF(INITY)™
A detailed guide to help implement DEFINITY® in your institution, including a summary of American Society of Echocardiography (ASE) Guidelines, discussion framework for roles and responsibilities for optimizing DEFINITY® use, and detailed instructions and troubleshooting tools.
UEA=ultrasound enhancing agent.
*Society of Diagnostic Medical Sonography (SDMS) credits are available for sonographers who enroll in these programs.
References:
-
Data on file, Lantheus.
-
Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810. doi:10.1016/j.jacc.2009.01.005
-
Main ML, Fu JW, Gundrum J, LaPointe NA, Gillam LD, Mulvagh SL. Impact of contrast echocardiography on outcomes in critically ill patients. Am J Cardiol. 2021;150:117-122. doi:10.1016/j.amjcard.2021.03.039
-
Lester SJ, Askew JW, Hurst RT, et al. Contrast echocardiography: experience in a clinical echocardiography laboratory. J Am Soc Echocardiogr. 2006;19(7):919-923. doi:10.1016/j.echo.2006.01.025
-
Ayesa SL, Katelaris AG, Brennan PC, Grieve SM. Medical imaging education opportunities for junior doctors and non-radiologist clinicians: a review. J Med Imaging Radiat Oncol. 2021;65(6):710-718. doi:10.1111/1754-9485.13266
INDICATION:
DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.
Assess all patients for the presence of any condition that precludes DEFINITY® administration.
Always have resuscitation equipment and trained personnel readily available.
CONTRAINDICATIONS:
Contraindicated in patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG).
WARNINGS AND PRECAUTIONS:
Serious Cardiopulmonary Reactions have occurred during or following administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias).
Serious Hypersensitivity Reactions have been observed during or shortly following administration including anaphylaxis, with manifestations that may include death. DEFINITY contains PEG and may increase risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG. Clinically assess patients for prior hypersensitivity reactions to products containing PEG. Monitor all patients for hypersensitivity reactions.
Systemic Embolization may occur in patients with a cardiac shunt. Assess patients with shunts for embolic phenomena following administration. DEFINITY is only for intravenous administration and must not be administered by intra-arterial injection.
There is a risk of Ventricular Arrhythmia Related to High Mechanical Index. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias. The maximum recommended mechanical index for use with DEFINITY is 0.8 in adult patients and 0.3 in pediatric patients.
Acute Pain Episodes in Patients with Sickle Cell Disease (SCD) shortly following administration have been reported. Discontinue DEFINITY in SCD patients experiencing new or worsening pain.
ADVERSE REACTIONS:
The most common adverse reactions (≥0.5%) are headache, back/renal pain, flushing, nausea, chest pain, injection site reactions, and dizziness.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.
Please see the accompanying full Prescribing Information and important safety information, including BOXED WARNING for serious cardiopulmonary reactions.
DEFINITY® Customer Service 1.800.299.3431
BACK TO TOP